Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. / Hall, Sara; Ohrfelt, Annika; Constantinescu, Radu; Andreasson, Ulf; Surova, Yulia; Boström, Fredrik; Nilsson, Christer; Widner, Håkan; Decraemer, Hilde; Nägga, Katarina; Minthon, Lennart; Londos, Elisabet; Vanmechelen, Eugeen; Holmberg, Bjorn; Zetterberg, Henrik; Blennow, Kaj; Hansson, Oskar.

I: Archives of Neurology, Vol. 69, Nr. 11, 2012, s. 1445-1452.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Hall, Sara ; Ohrfelt, Annika ; Constantinescu, Radu ; Andreasson, Ulf ; Surova, Yulia ; Boström, Fredrik ; Nilsson, Christer ; Widner, Håkan ; Decraemer, Hilde ; Nägga, Katarina ; Minthon, Lennart ; Londos, Elisabet ; Vanmechelen, Eugeen ; Holmberg, Bjorn ; Zetterberg, Henrik ; Blennow, Kaj ; Hansson, Oskar. / Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. I: Archives of Neurology. 2012 ; Vol. 69, Nr. 11. s. 1445-1452.

RIS

TY - JOUR

T1 - Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

AU - Hall, Sara

AU - Ohrfelt, Annika

AU - Constantinescu, Radu

AU - Andreasson, Ulf

AU - Surova, Yulia

AU - Boström, Fredrik

AU - Nilsson, Christer

AU - Widner, Håkan

AU - Decraemer, Hilde

AU - Nägga, Katarina

AU - Minthon, Lennart

AU - Londos, Elisabet

AU - Vanmechelen, Eugeen

AU - Holmberg, Bjorn

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Hansson, Oskar

PY - 2012

Y1 - 2012

N2 - Objective: To assess the ability of 5 cerebrospinal fluid (CSF) biomarkers to differentiate between common dementia and parkinsonian disorders. Design: A cross-sectional, clinic-based study. Participants: Cerebrospinal fluid samples (N=453) were obtained from healthy individuals serving as controls and from patients with Parkinson disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), Alzheimer disease (AD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD). Setting: Neurology and memory disorder clinics. Main Outcome Measures: Cerebrospinal fluid biomarker levels in relation to clinical diagnosis. Results: Cerebrospinal fluid levels of alpha-synuclein were decreased in patients with PD, PDD, DLB, and MSA but increased in patients with AD. Cerebrospinal fluid levels of beta-amyloid 1-42 were decreased in DLB and even further decreased in AD. Cerebrospinal fluid levels of total tau and hyperphosphorylated tau were increased in AD. Multivariate analysis revealed that these biomarkers could differentiate AD from DLB and PDD with an area under the curve of 0.90, with alpha-synuclein and total tau contributing most to the model. Cerebrospinal fluid levels of neurofilament light chain were substantially increased in atypical parkinsonian disorders (ie, PSP, MSA, and CBD), and multivariate analysis revealed that the level of neurofilament light chain alone could differentiate PD from atypical parkinsonian disorders, with an area under the curve of 0.93. Conclusions: Ascertainment of the alpha-synuclein level in CSF somewhat improves the differential diagnosis of AD vs DLB and PDD when combined with established AD biomarkers. The level of neurofilament light chain alone may differentiate PD from atypical parkinsonian disorders.

AB - Objective: To assess the ability of 5 cerebrospinal fluid (CSF) biomarkers to differentiate between common dementia and parkinsonian disorders. Design: A cross-sectional, clinic-based study. Participants: Cerebrospinal fluid samples (N=453) were obtained from healthy individuals serving as controls and from patients with Parkinson disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), Alzheimer disease (AD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD). Setting: Neurology and memory disorder clinics. Main Outcome Measures: Cerebrospinal fluid biomarker levels in relation to clinical diagnosis. Results: Cerebrospinal fluid levels of alpha-synuclein were decreased in patients with PD, PDD, DLB, and MSA but increased in patients with AD. Cerebrospinal fluid levels of beta-amyloid 1-42 were decreased in DLB and even further decreased in AD. Cerebrospinal fluid levels of total tau and hyperphosphorylated tau were increased in AD. Multivariate analysis revealed that these biomarkers could differentiate AD from DLB and PDD with an area under the curve of 0.90, with alpha-synuclein and total tau contributing most to the model. Cerebrospinal fluid levels of neurofilament light chain were substantially increased in atypical parkinsonian disorders (ie, PSP, MSA, and CBD), and multivariate analysis revealed that the level of neurofilament light chain alone could differentiate PD from atypical parkinsonian disorders, with an area under the curve of 0.93. Conclusions: Ascertainment of the alpha-synuclein level in CSF somewhat improves the differential diagnosis of AD vs DLB and PDD when combined with established AD biomarkers. The level of neurofilament light chain alone may differentiate PD from atypical parkinsonian disorders.

U2 - 10.1001/archneurol.2012.1654

DO - 10.1001/archneurol.2012.1654

M3 - Article

VL - 69

SP - 1445

EP - 1452

JO - Archives of Neurology

T2 - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 11

ER -